TY - JOUR
T1 - The pro-resolving mediator, annexin A1 regulates blood pressure, and age-associated changes in cardiovascular function and remodeling
AU - Singh, Jaideep
AU - Jackson, Kristy L.
AU - Tang, Feng Shii
AU - Fu, Ting
AU - Nowell, Cameron
AU - Salimova, Ekaterina
AU - Kiriazis, Helen
AU - Ritchie, Rebecca H.
AU - Head, Geoffrey A.
AU - Woodman, Owen L.
AU - Qin, Cheng Xue
N1 - Funding Information:
The authors acknowledge the technical assistance of the Monash Histology Platform, Department of Anatomy and Developmental Biology, Monash University, and the facilities and scientific and technical assistance of the National Imaging Facility (NIF), a National Collaborative Research Infrastructure Strategy (NCRIS) capability at Monash Biomedical Imaging (MBI), a Technology Research Platform at Monash University. The graphical abstract was created using elements and templates from BioRender.com. Open access publishing facilitated by Monash University, as part of the Wiley - Monash University agreement via the Council of Australian University Librarians.
Funding Information:
This work was partly funded by a Vanguard grant (APP102885) from the National Heart Foundation of Australia (NHF) (to C.X.Q., K.J., and R.H.R) and the Victorian Government of Australia's Operational Infrastructure Support Program. C.X.Q. is supported by an NHF Future Leader Fellowship. K.J. is supported by NHMRC ECR Fellowship. J.S. is supported by Monash Graduate Scholarship.
Publisher Copyright:
© 2024 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
PY - 2024/2/15
Y1 - 2024/2/15
N2 - Aging is associated with chronic, low-level inflammation which may contribute to cardiovascular pathologies such as hypertension and atherosclerosis. This chronic inflammation may be opposed by endogenous mechanisms to limit inflammation, for example, by the actions of annexin A1 (ANXA1), an endogenous glucocorticoid-regulated protein that has anti-inflammatory and pro-resolving activity. We hypothesized the pro-resolving mediator ANXA1 protects against age-induced changes in blood pressure (BP), cardiovascular structure and function, and cardiac senescence. BP was measured monthly in conscious mature (4-month) and middle-aged (12-month) ANXA1-deficient (ANXA1−/−) and wild-type C57BL/6 mice. Body composition was measured using EchoMRI, and both cardiac and vascular function using ultrasound imaging. Cardiac hypertrophy, fibrosis and senescence, vascular fibrosis, elastin, and calcification were assessed histologically. Gene expression relevant to structural remodeling, inflammation, and cardiomyocyte senescence were also quantified. In C57BL/6 mice, progression from 4 to 12 months of age did not affect the majority of cardiovascular parameters measured, with the exception of mild cardiac hypertrophy, vascular calcium, and collagen deposition. Interestingly, ANXA1−/− mice exhibited higher BP, regardless of age. Additionally, age progression had a marked impact in ANXA1−/− mice, with markedly augmented vascular remodeling, impaired vascular distensibility, and body composition. Consistent with vascular dysfunction, cardiac dysfunction, and hypertrophy were also evident, together with markers of senescence and inflammation. These findings suggest that endogenous ANXA1 plays a critical role in regulating BP, cardiovascular function, and remodeling and delays cardiac senescence. Our findings support the development of novel ANXA1-based therapies to prevent age-related cardiovascular pathologies.
AB - Aging is associated with chronic, low-level inflammation which may contribute to cardiovascular pathologies such as hypertension and atherosclerosis. This chronic inflammation may be opposed by endogenous mechanisms to limit inflammation, for example, by the actions of annexin A1 (ANXA1), an endogenous glucocorticoid-regulated protein that has anti-inflammatory and pro-resolving activity. We hypothesized the pro-resolving mediator ANXA1 protects against age-induced changes in blood pressure (BP), cardiovascular structure and function, and cardiac senescence. BP was measured monthly in conscious mature (4-month) and middle-aged (12-month) ANXA1-deficient (ANXA1−/−) and wild-type C57BL/6 mice. Body composition was measured using EchoMRI, and both cardiac and vascular function using ultrasound imaging. Cardiac hypertrophy, fibrosis and senescence, vascular fibrosis, elastin, and calcification were assessed histologically. Gene expression relevant to structural remodeling, inflammation, and cardiomyocyte senescence were also quantified. In C57BL/6 mice, progression from 4 to 12 months of age did not affect the majority of cardiovascular parameters measured, with the exception of mild cardiac hypertrophy, vascular calcium, and collagen deposition. Interestingly, ANXA1−/− mice exhibited higher BP, regardless of age. Additionally, age progression had a marked impact in ANXA1−/− mice, with markedly augmented vascular remodeling, impaired vascular distensibility, and body composition. Consistent with vascular dysfunction, cardiac dysfunction, and hypertrophy were also evident, together with markers of senescence and inflammation. These findings suggest that endogenous ANXA1 plays a critical role in regulating BP, cardiovascular function, and remodeling and delays cardiac senescence. Our findings support the development of novel ANXA1-based therapies to prevent age-related cardiovascular pathologies.
KW - ANXA1
KW - blood pressure
KW - cardiovascular remodeling
KW - inflammation
KW - senescence
UR - http://www.scopus.com/inward/record.url?scp=85184233337&partnerID=8YFLogxK
U2 - 10.1096/fj.202301802R
DO - 10.1096/fj.202301802R
M3 - Article
C2 - 38318648
AN - SCOPUS:85184233337
SN - 0892-6638
VL - 38
JO - The FASEB Journal
JF - The FASEB Journal
IS - 3
M1 - e23457
ER -